NCT03861910

Brief Summary

Food allergy is a common chronic condition in childhood. Recent studies have suggested that the natural history of food allergy has changed during the last two decades, with an increased prevalence, severity of clinical manifestations, and risk of persistence into later ages. The increased food allergy prevalence in children has an important economic impact, with significant direct costs for the healthcare system and even larger costs for the families of food-allergic patients. In addition, children with food allergies are at increased risk to develop other allergic manifestations later in life. According to a recent study, children with a food allergy are 2 to 4 times more likely to develop other atopic manifestations such as asthma (4.0 times), atopic eczema (2.4 times), and respiratory allergies (3.6 times), compared to children without a food allergy. Cow's milk allergy is among the most common food allergy in early childhood, with an estimated prevalence of 2% to 3%. It has been previously showed that in children with cow milk allergy, an extensively hydrolysed casein formula supplemented with the probiotic Lactobacillus rhamnosus GG induced higher tolerance rates compared to extensively hydrolysed casein formula without Lactobacillus rhamnosus GG and other formulas. These findings were consistent with those of a 1-year follow-up study performed in the US that showed better outcomes using an extensively hydrolysed casein formula+Lactobacillus rhamnosus GG vs. an extensively hydrolysed casein formula or amino acid-based formula for the first-line dietary management of cow milk allergy. In addition it has been recently demonstrated that extensively hydrolysed casein formula + Lactobacillus rhamnosus GG reduces the incidence of other atopic manifestations and hastens the development of oral tolerance in children with IgE-mediated cow milk allergy. The present randomized controlled trial (RCT) was designed to test whether different dietary interventions could influence the occurrence of other atopic manifestations in children with IgE-mediated cow milk allergy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
365

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2014

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2014

Completed
4.2 years until next milestone

First Submitted

Initial submission to the registry

February 21, 2019

Completed
11 days until next milestone

First Posted

Study publicly available on registry

March 4, 2019

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2020

Completed
1.6 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2021

Completed
Last Updated

June 26, 2024

Status Verified

June 1, 2024

Enrollment Period

5.4 years

First QC Date

February 21, 2019

Last Update Submit

June 25, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Rate of subjects with occurrence of other of allergic manifestations

    To evaluate the effect of different dietary strategies on the occurrence of eczema, urticaria, asthma and rhinoconjunctivitis in children with IgE-mediated cow milk allergy

    3 years

Secondary Outcomes (7)

  • Rate of subjects with tolerance acquisition to cow's milk

    3 years

  • Change in metagenomics and metabolomics

    3 years

  • Epigenetic modifications in cytokines genes

    3 years

  • Epigenetic modifications in cytokines genes

    3 years

  • Rate of subjects with occurrence of other of allergic manifestations

    after 4 to 6 years follow-up

  • +2 more secondary outcomes

Study Arms (5)

extensively hydrolyzed casein formula+LGG

subjects with IgE mediated cow milk allergy treated with extensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG as exclusion diet

Dietary Supplement: hypoallergenic formulas

extensively hydrolyzed whey formula;

subjects with IgE mediated cow milk allergy treated with extensively hydrolyzed whey formula as exclusion diet

Dietary Supplement: hypoallergenic formulas

hydrolyzed rice formula

subjects with IgE mediated cow milk allergy treated with hydrolyzed rice formula as exclusion diet

Dietary Supplement: hypoallergenic formulas

soy based formula

subjects with IgE mediated cow milk allergy treated with soy based formula as exclusion diet

Dietary Supplement: hypoallergenic formulas

amino-acid based formula

subjects with IgE mediated cow milk allergy treated with amino-acid based formula as exclusion diet

Dietary Supplement: hypoallergenic formulas

Interventions

hypoallergenic formulasDIETARY_SUPPLEMENT

hypoallergenic formulas used for cow milk allergy treatment

amino-acid based formulaextensively hydrolyzed casein formula+LGGextensively hydrolyzed whey formula;hydrolyzed rice formulasoy based formula

Eligibility Criteria

Age1 Month - 12 Months
Sexall
Age GroupsChild (0-17)
Sampling MethodProbability Sample
Study Population

Children who were consecutively observed at a FP office because the recent occurrence of signs and symptoms possibly related to IgE-mediated CMA were sent to our tertiary centre for paediatric allergy for possible inclusion in the study. Only subjects who met the inclusion criteria will be invited to participate to the study.Written informed consent will be obtained from the parents of each subject. Anamnestic, demographic, anthropometric and clinical data, as well as information on socio-demographic factors, family and living conditions, parental history of allergic diseases, maternal smoking during pregnancy, environmental tobacco smoke exposure, number of siblings, and pet ownership were obtained from the parents and recorded in a clinical database. For children with sure diagnosis of IgE-mediated CMA during a 3-year follow-up,3 visits every 12 months will be performed. Stool samples for metagenomics and metabolomics and blood sample for epigenetics studies will be collected.

You may qualify if:

  • age 1-12 months
  • IgE-mediated CMA

You may not qualify if:

  • cow's milk protein-induced anaphylaxis,
  • food protein induced enterocolitis syndrome,
  • other food allergies,
  • other allergic diseases,
  • non-CMA-related atopic eczema,
  • eosinophilic disorders of the gastrointestinal tract,
  • chronic systemic diseases,
  • congenital cardiac defects,
  • active tuberculosis,
  • autoimmune diseases,
  • immunodeficiency,
  • chronic inflammatory bowel diseases,
  • celiac disease,
  • cystic fibrosis,
  • metabolic diseases,
  • +4 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Naples Federico II

Naples, 80131, Italy

Location

MeSH Terms

Conditions

Milk HypersensitivityFood HypersensitivityConjunctivitis, Allergic

Condition Hierarchy (Ancestors)

Hypersensitivity, ImmediateHypersensitivityImmune System DiseasesConjunctivitisConjunctival DiseasesEye Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

February 21, 2019

First Posted

March 4, 2019

Study Start

December 1, 2014

Primary Completion

May 1, 2020

Study Completion

December 1, 2021

Last Updated

June 26, 2024

Record last verified: 2024-06

Locations